乳癌诊断市场规模、份额、成长分析、按类型、产品、癌症类型、应用、最终用户、地区 - 产业预测，2025-2032 年

预计 2023 年乳癌诊断市场规模将达到 56 亿美元，并从 2024 年的 60.4 亿美元成长到 2032 年的 110.1 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.8%。

由于迫切需要增强的检测解决方案，乳癌诊断市场正在迅速发展。由于乳癌通常没有早期症状，人工智慧技术在解决患者诊断方面变得至关重要，例如 Paragon Biosciences LLC推出的 Qlarity Imaging LLC，该公司正在寻求 FDA 批准其用于乳房诊断的人工智慧系统。越来越多的公司在各种成像方式中利用人工智慧，为医疗保健提供者提供经济高效的解决方案。印度私人诊断中心的兴起，例如FUJIFILM的 NURA 健康筛检中心，是为了满足人们对影像诊断服务日益增长的需求，因为由于公立医院的服务有限，私人诊断中心可以取代公立医院。此外，在发展中地区，在西门子、通用电气医疗和飞利浦等行业努力的支持下，整修的诊断成像设备作为一种经济高效的选择越来越受欢迎，以推广高品质的再生医学系统。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术进步

乳癌诊断药物市场规模（按类型）

• 市场概况
• 影像诊断
  • 乳房X光检查
  • MRI
  • 超音波
  • PET/CT
• 切片检查
• 基因组检测
• 血液检查
• 其他的

乳癌诊断药物市场规模（依产品划分）

• 市场概况
• 基于平台的产品
  • 次世代定序
  • 微阵列
  • PCR
  • 其他的
• 仪器仪表类产品
  • 影像诊断
  • 切片检查

乳癌诊断药物市场规模（按癌症类型）

• 市场概况
• 乳管癌（乳管原位癌）
• 浸润性乳管癌
• 发炎性乳癌
• 转移性乳癌

乳癌诊断药物市场规模（按应用）

• 市场概况
• 筛检
• 诊断和预后
• 预后
• 调查
• 其他的

乳癌诊断药物市场规模（按最终用户划分）

• 市场概况
• 医院和诊所
• 诊断中心
• 医学研究实验室
• 其他的

乳癌诊断药物市场规模

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Hologic（USA）
• Natera（USA）
• Siemens Healthineers（Germany）
• Leica Biosystems（Germany）（Parent company：Danaher Corporation）
• Roche Diagnostics（Switzerland）
• GE Healthcare（USA）
• Philips Healthcare（Netherlands）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Becton, Dickinson and Company（USA）
• Agilent Technologies（USA）
• Illumina（USA）
• PerkinElmer（USA）
• Qiagen（Germany）
• Bio-Rad Laboratories（USA）
• Cepheid（USA）（Parent company：Danaher Corporation）
• Myriad Genetics（USA）
• Fujifilm Holdings Corporation（Japan）
• Canon Medical Systems Corporation（Japan）
• Hitachi Medical Systems（Japan）

结论和建议

Breast Cancer Diagnostics Market size was valued at USD 5.6 billion in 2023 and is poised to grow from USD 6.04 billion in 2024 to USD 11.01 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The breast cancer diagnostics market is evolving rapidly, driven by the urgent need for enhanced detection solutions. With breast cancer often presenting no early symptoms, AI technologies are becoming pivotal in addressing patient diagnostics, exemplified by Paragon Biosciences LLC's launch of Qlarity Imaging LLC, which aims for FDA clearance of an AI system for breast diagnostics. Companies are increasingly utilizing AI across various imaging modalities, presenting cost-effective solutions for healthcare providers. The rise of private diagnostic centers, like FUJIFILM Corporation's NURA in India, is a response to increased demand for imaging services, driven by public hospital limitations. Additionally, in developing regions, refurbished imaging equipment is gaining traction as a cost-effective alternative, supported by industry initiatives from Siemens, GE Healthcare, and Philips to promote quality refurbished systems.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is primarily driven by technological advancements, including state-of-the-art imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations have greatly enhanced the accuracy and efficiency of breast cancer detection and diagnosis, leading to their widespread adoption among healthcare professionals. The continuous development of sophisticated diagnostic tools not only improves patient outcomes but also propels market growth by meeting the increasing demand for reliable and effective breast cancer screening solutions. As these technologies evolve, they further reinforce the importance of early detection and timely intervention in combating breast cancer.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and the social stigma associated with breast cancer can significantly hinder women's willingness to participate in screening and diagnostic tests. These factors often lead to a reluctance to seek necessary medical attention, ultimately affecting the rates of early detection and diagnosis. As a result, many women might avoid or postpone crucial evaluations due to fear, misconceptions, or societal pressures. This resistance not only increases the risk of late-stage diagnosis but also poses a challenge to the overall effectiveness of breast cancer diagnostics in improving patient outcomes. Overcoming these barriers is essential for enhancing early intervention and promoting better health practices.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is witnessing a significant trend towards the adoption of liquid biopsies, which analyze circulating tumor cells and cell-free DNA from blood samples. This non-invasive approach is particularly appealing for early detection and real-time monitoring of treatment efficacy, thereby enhancing patient outcomes. As healthcare providers and patients increasingly seek alternatives to traditional tissue biopsies, the demand for liquid biopsy solutions is surging. Coupled with advancements in molecular biology and personalized medicine, this trend is expected to drive innovation, investment, and growth within the breast cancer diagnostics landscape, positioning liquid biopsies as a cornerstone in future clinical practices.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2025-2032)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Medical Laboratories
• Others

Global Breast Cancer Diagnostics Market Size & CAGR (2025-2032)

• North America (Type, Product, Cancer Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Product, Cancer Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Cancer Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Cancer Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Cancer Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hologic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations